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Multiple observations suggest a cell type-specific role for TP53 in mammary epithelia. We developed an in
vitro assay, in which primary mouse mammary epithelial cells (mMECs) progressed from lumenal to
basal-like phenotypes based on expression of Krt18 or DNp63, respectively. Such transition was markedly
delayed in Trp53-/- mMECs suggesting that Trp53 is required for specification of the basal, but not lumenal
cells. Evidence from human basal-like cell lines suggests that TP53 may support the activity of DNp63 by
preventing its translocation from nucleoplasm into nucleoli. In human lumenal cells, activation of TP53 by
inhibiting MDM2 or BRCA1 restored the nucleoplasmic expression of DNp63. Trp53-/- mMECs eventually
lost epithelial features resulting in upregulation of MDM2 and translocation of DNp63 into nucleoli. We
propose that TP63 may contribute to TP53-mediated oncogenic transformation of epithelial cells and shed
light on tissue- and cell type-specific biases observed for TP53-related cancers.
T
P53 is a bona fide tumor suppressor somatically mutated in almost half of all human cancers. Its tumor
suppressor activity is typically ascribed to its role as a transcription factor regulating expression of genes
involved in control of cell cycle, cellular senescence, and apoptosis1. Aberrations in such common cellular
processes, however, do not explain known p53-associated developmental defects in embryonic tissues of epi-
dermal origin in female mice or a strong tissue-specific bias in the tumor spectrum. Trp53 knock-out mice mostly
develop lymphomas and sarcomas2–4, while concurrent mutations in someDNA repair genes may, however, shift
the tumor spectrum toward epithelia-derived carcinomas5. In addition, while cancer-associated point mutations
in the TP53 gene are equally common in both lumenal and basal-like breast cancers, truncating mutations and
large scale deletions in this gene are more prevalent in basal-like breast cancers compared with the lumenal
subtypes suggesting that different cell types within mammary epithelia may have different requirements for
TP536.
Mammary glands are ectodermal organs composed of twomajor cell types: lumenal cells form the inner layer of
the mammary ducts and alveoli, and produce milk as their primary function; basal myoepithelial cells synthesize
the basement membrane separating mammary epithelia from surrounding adipose tissues and provide a con-
tractile function for milk secretion. Mammary lumenal cells are commonly characterized by expression of
cytokeratins 8 and 18 (KRT8/18), while basal epithelial cells, in contrast, express cytokeratins 5 and 14 (KRT
5/14) and an isoform of TP63 known asDNp637. TP63 is amember of the p53 protein family sharing an extensive
sequence similarity, oligomerization and DNA binding abilities8. The DNp63 isoform is transcribed from an
alternative promoter located in the third intron and, in contrast to the full-length isoform known as TAp63, lacks
the transactivation domain at the amino-terminus9. TAp63 transactivates many of the TP53-regulated genes,
while DNp63 lacks this capacity and is thought to function in a dominant negative fashion9. In contrast to TP53,
TP63 is rarely mutated in cancers and is known to play essential developmental functions10,11. TAp63 is almost
undetectable in adult tissues except for oocytes and rapidly renewing B-lymphocytes, but induced during wound
healing and genotoxic stress while DNp63 is widely expressed in the basal layers of multiple epithelial tissues
OPEN
SUBJECT AREAS:
BREAST CANCER
DIFFERENTIATION
NUCLEOLUS
MOUSE
Received
14 October 2013
Accepted
27 March 2014
Published
11 April 2014
Correspondence and
requests for materials
should be addressed to
S.G.K. (sergey.
kuznetsov@helsinki.fi)
SCIENTIFIC REPORTS | 4 : 4663 | DOI: 10.1038/srep04663 1
where it plays essential and complex roles in stem cell maintenance
and differentiation12–16. Given such essential roles that TP63 plays in
epidermal tissues, and the presence of multiple TP53 binding sites in
both promoters ofTP63 (Supplementary Figure S1), it is possible that
TP63may serve as a mediator of the cell type-specific effects of TP53.
No cell type-restricted abnormalities within mammary epithelia
are reported for existing Trp53-mutated mouse models except for a
delayed involution after pregnancy, which is likely related to its pro-
apoptotic function4. To reveal possible effects of Trp53 on the differ-
entiation of lumenal and basal epithelial lineages, we developed an in
vitro differentiation assay, in which primary mouse mammary epi-
thelial cells (mMECs) are explanted in a plastic dish and their dif-
ferentiation is monitored using cell type-specific markers over time.
Our data demonstrate that Trp53 is required for differentiation of
basal epithelial cells, while having an opposite effect on the lumenal
cells. Studies on human mammary epithelial cell lines suggest that in
basal epithelial cells, TP53 inhibits expression of the TAp63 isoform,
while supporting the activity of DNp63. Our experiments indicate
that inactivation of DNp63 may occur by sequestering the protein in
nucleoli. This work suggests that TP63may be an essential compon-
ent of the TP53-mediated oncogenic transformation of epidermal
cells.
Results
Loss of p53 inhibits differentiation of basal-like mammary cells.
To reveal a role of Trp53 in the differentiation of lumenal and basal
mammary epithelial lineages, we developed an in vitro differentiation
system, in which freshly isolated mMECs gradually, in a course of 12
days, switched expression of lineage markers from lumenal to basal,
eventually losing them altogether (Figure 1). Here, Krt18 detected by
immunofluorescence was used as a marker of lumenal (Figure 1a–d,
and i–l), andDNp63 – as amarker of basal differentiation (Figure 1e–
h, and m–p). Most wild type mMECs expressed only the lumenal
marker for the first three days in culture (Figure 1a), which became
weaker at day 6, and essentially disappeared by day 9 (Figure 1b, c). In
contrast, the basal marker DNp63 could be reliably detected only
after six days in culture (Figure 1e–g). These phenotypic changes
were independently confirmed using wild type primary mMECs
isolated from reporter mice expressing a red (RFP) and cyan (CFP)
fluorescent proteins under a Krt18 or Krt5 promoters serving as a
lumenal or basal markers, respectively (Supplementary Figure S2).
There, both RFP- and CFP-positive cells could be found during the
first 2 days in culture, while only the CFP reporter was evidently
expressed in all cells after 5 days, and both disappeared on day 7 in
culture (Supplementary Figure S2). Unlike wild type cells, Trp53-/-
mMECs demonstrated a sustained Krt18 expression even after nine
days in culture (Figure 1i–k), while DNp63 remained weakly
expressed at days 3 and 6, becoming stronger only at day 9
(Figure 1m–o). Together, this suggests that Trp53 counteracts the
lumenal differentiation and promotes the basal-like lineage.
EMT correlates with a relocation ofDNp63 from the nucleoplasm
into nucleoli. At day 12 both wild type and Trp53-/- mMECs stained
negative for Krt18 (Figure 1d,l). Most wild typemMECs also stopped
proliferating around this time and morphologically resembled sen-
escent fibroblasts (data not shown). In contrast, Trp53-/- mMECs
could proliferate indefinitely consistent with a reported ability of a
mutant Trp53 to immortalize primary cells17. Extensively cultured
Trp53-/- mMECs lost expression of both lumenal and basal keratins,
Krt18 and Krt5, respectively (Figure 2a). They also upregulated ame-
senchymal marker Vimentin (Figure 2a), suggesting that mMECs
undergo an epithelial-to-mesenchymal transition (EMT) when cul-
tured on plastic. Loss of Trp53 was reported to promote EMT18 and,
indeed, even at the earliest passage colonies of Trp53-/- mMECs were
less compact than the wild type counterparts and morphologically
resembled fibroblasts or mesenchymal cells rather than polarized
cuboidal epithelial cells (Figure 2b). These morphological changes
progressed even further when Trp53-/- mMECs were cultured for
eight passages (Figure 2b).
This loss of epithelial features in mMECs also affected such an
important epithelial regulator as DNp63 protein. While in primary
mMECs at 9 days in culture DNp63 protein was found in the
nucleoplasm excluded from nucleoli (Figure 1g, o), its localization
switched to the opposite three days later with most of the protein
now found in nucleoli (Figure 1h, p). Therefore, we hypothesized
that the nucleolar localization of DNp63 is related to the EMT
process. To test this hypothesis, we stained basal human mam-
mary epithelial cell lines HCC1937 and MCF10A with a cobble-
stone-like morphology and found the DNp63 protein exclusively
in the nucleoplasm (Figure 3a, middle row, and Figure 3c).
Exclusion of DNp63 from nucleoli in MCF10A cells was con-
firmed by a co-staining with a nucleolar phosphoprotein B23 also
known as nucleophosmin (NPM) (Figure 3c). In contrast, in a
mesenchymal-like cell line MDA-MB-231, DNp63 was not
excluded from nucleoli (Figure 3a, c). Furthermore, MCF10A cells
were reported to assume a spindle-like morphology when plated at
a low density (compare Figure 3a and b)19. In such conditions, the
DNp63 protein was found predominantly in nucleoli (Figure 3b).
This suggests that DNp63 shuffles between the nucleoplasm and
nucleoli in connection with changes between epithelial and
mesenchymal appearances.
What is the functional difference between DNp63 located in the
nucleoplasm or nucleoli? Silencing of DNp63 is known to increase
migratory properties of cancer cells, while its lower expression level
in tumors is associated with an increased expression of EMT-pro-
moting transcription factors Snail and Slug20. Therefore, we hypothe-
Figure 1 | Loss of Trp53 in mMECs cultured in adhesive conditions
delays their transition from a luminal to basal-like phenotype. Freshly
isolated Trp531/1 (a–h) and Trp53-/- (i–p) primary mMECs were cultured
in plastic dishes and sampled every three days. (a–d, i–l) Luminal
differentiation was monitored by immunofluorescence staining for
cytokeratin 18 (Krt18, green). (e–h, m–p) Basal differentiation was
monitored by staining for DNp63 (red). Insets in (g, h, o, and p)
demonstrate selected nuclei at a higher magnification. Arrowheads
indicate DNp63 excluded from nucleoli. Arrows show DNp63 located in
nucleoli. Scale bars correspond to 20 mm.
www.nature.com/scientificreports
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sized that translocation of theDNp63 protein into nucleoli reflects its
functional inactivation. To test this, we used trichostatin A (TSA), a
potent inhibitor of histone deacetylases 1 and 2 (HDAC1/2), which
are important for DNp63-mediated transcriptional repression21, to
inhibit DNp63 in epithelial-like MCF10A and HCC1937 cells. Such
treatment resulted in a nucleolar translocation of DNp63 in these
cells (Figure 3a, bottom row). However in mesenchymal-like MDA-
MB-231 cells, DNp63 remained in nucleoli regardless of the TSA
treatment (Figure 3a). These data support the view that the nucleolar
DNp63 protein is equivalent to its functional inactivation, and pro-
motes the EMT process.
TP53 and DNp63 in basal cells are antagonized by TAp63. As
mentioned earlier, DNp63 is an alternative product of the TP63
gene, lacking the transactivation domain. Multiple studies demon-
strated an inverse correlation between DNp63 and TAp63 isoforms9.
Having found a negative effect of theTrp53-deletion on expression of
DNp63, we sought to extend our analysis to the TAp63 isoform.Wild
type mMECs cultured for 14 days lost expression of both isoforms of
Trp63 (Figure 4a). At the same time the Trp53-/- mMECs strongly
upregulated the TAp63, but not the DNp63 isoform (Figure 4a). An
isoform-specific antibody staining of immortalized Trp53-/- mMECs
revealed the TAp63 protein located in nucleoli (Figure 4b)22. This
suggested that a high expression of TAp63 could be directly regulated
by Trp53. To address this question, we stained four human mam-
mary cell lines for the TAp63 protein isoform (Figure 4c). Surpri-
singly, TAp63 protein was expressed in nucleoli in all cell lines
without apparent differences between TP53-mutated (HCC1937
and MDA-MB-231) and TP53-wild type cells (MCF7 and
MCF10A), or between basal-like epithelial cells showing either a
nucleoplasmic (HCC1937 and MCF10A, Figure 4c) or a nucleolar
(MDA-MB-231, Figure 3f) localization of DNp63 protein.
Nevertheless, inhibition of DNp63 in MCF10A cells using the TSA
treatment led to a 36-fold increase in the TAp63 expression level
supporting the idea that DNp63 negatively regulates TAp63
(Figure 4d). In addition, our analysis of isogenic MCF10A cells
after a genetic deletion of TP53 revealed a two-fold increase of
TAp63 expression level (Figure 4e). Furthermore, an isoform-
specific knockdown of DNp63 in TP531/1 MCF10A cells resulted
in a 2-fold increase in TAp63 mRNA, but not vice versa (Figure 4f).
However, in isogenic TP53-/- MCF10A cells knockdown of DNp63
lead to a 2.5-fold higher TAp63, while knockdown of TAp63 resulted
in a 2-fold increase in DNp63 (Figure 2g). Taken together, this
indicates that expression of TAp63 is controlled by DNp63 and
TP53. The fact that TAp63 is barely expressed in most adult cell
types in vivo but readily found in cell lines, supports the view
proposed elsewhere that the TAp63 isoform is essential to sustain
the self-renewal capacity23.
Activation of TP53 in lumenal cells forces expression of basal
markers. If deletion of Trp53 were indeed the reason for a delayed
switch from lumenal to basal markers observed in primary mMEC
cultures, we would expect that an activation of TP53 in lumenal cells
would force them to express basal-like markers. TP53 is mainly
controlled by E3 ubiquitin ligases MDM2 and MDM4 that bind
TP53 and target it for a proteasomal degradation24,25. Therefore, we
pharmacologically inhibited MDM4 using a pseudourea derivative
XI-001 in the lumenal breast cancer cell line MCF7 carrying a wild
type TP53 gene and, indeed, observed a strong re-expression of the
TP53 protein (Supplementary Figure 3). An inhibition of MDM2
with Serdemetan, a specific compound blocking its E3 ligase
activity led to a similar result (Figure 5a). As expected, this
treatment increased the expression level of a basal marker DNp63
in lumenal MCF7 cells almost 10-fold, which located in the
nucleoplasm, but not in nucleoli (Figure 5a, b). The same effect on
the DNp63 protein was obtained when we knocked-down MDM2
using a specific siRNA (Figure 5a). Interestingly, the level of DNp63
mRNA was reduced after the siRNA-mediated knockdown of
Figure 2 | Trp53-/- mMECs acquire mesenchymal features in vitro. (a) Expression of a mesenchymal marker Vimentin increases, while that of epithelial
keratins (Krt18 and Krt14) decreases with time, when mMEC cultures at 6 days and 4 weeks were compared using qRT-PCR. The bar plot shows the
mRNA expression as a fold change relative to wild type mMECs. (b) Phase contrast images illustrate a spindle-shaped morphology of primary Trp53-/-
mMECs (middle) in contrast to a tight epithelial sheet of wild type mMECs (left). Extensively passaged Trp53-/- mMECs morphologically resemble
fibroblasts (right). Scale bars correspond to 100 mm.
www.nature.com/scientificreports
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MDM2 in spite of the visible increase in the corresponding protein
(Figure 5a, b). This suggests either that a pharmacological inhibition
ofMDM2 has a broader specificity than the siRNA or that regulation
of DNp63 occurs mostly at the post-translational level. Either way,
the data confirm that a reactivation of the TP53 pathway in a lumenal
cell line can, indeed, lead to expression of basal-specific differentia-
tion markers.
Another way to activate the TP53 pathway is to induce DNA
damage checkpoints by inhibiting DNA repair, e.g. via inactivation
of BRCA1. BRCA1 is a critical mediator of the homologous recom-
bination pathway of DNA repair. Its germ-line mutations predispose
to breast cancers, which tend to have a basal-like phenotype26. It is
demonstrated, however, that basal BRCA1-related breast cancers
originate from lumenal progenitor cells27. Inhibition of BRCA1 in
lumenal MCF7 cells using a specific siRNA resulted in a strongly
upregulated basal marker, DNp63 protein, both at the mRNA and
protein levels (Figure 5a, b, c). This also led to a transcriptional
repression of MDM2 (Figure 5b). Equally, inhibition of MDM2
either with Serdemetan or a siRNA suppressed BRCA1 (Figure 5a,
b, c) revealing a strong correlation between these two genes.
Somewhat unexpectedly, we found that placing lumenal MCF7
cells into the DMEM/F12 medium, normally used to maintain
basal-like MCF10A cells, led to the activation of TP53 protein
expression (Supplementary Figure S3). Consistent with the previous
observations, this treatment also induced a strong expression of the
basal marker DNp63 and suppressed BRCA1 and MDM2 (Supple-
mentary Figure 4). When now TP53 was inhibited using a specific
siRNA, DNp63 protein translocated into nucleoli (Supplementary
Figure 4) suggesting its functional inactivation and further support-
ing a direct link between these genes. In addition, the expression of
BRCA1 and MDM2 greatly increased (Supplementary Figure 4).
These results establish an association of BRCA1 and MDM2 with
the lumenal subtype as opposed to TP53 and DNp63 associated with
the basal epithelial subtype, and suggest that a switch from the lume-
nal to basal phenotypes is coordinately regulated by TP53, DNp63,
MDM2/4, and BRCA1.
Deletion of TP53 in basal cells induces expression of lumenal
markers. Non-transformed human basal-like mammary epithelial
MCF10A cells express high levels of DNp63 and low levels of
MDM2 and BRCA1 relative to the lumenal MCF7 cells (compare
Figure 5a, and Figure 6a). As inhibition of BRCA1 or MDM2 in
lumenal cells resulted in induction of basal-like marker DNp63, we
asked whether the opposite would be true for basal-like cells. We
found that a siRNA-mediated knock-down of TP63 inMCF10A cells
increased the expression levels of MDM2 and BRCA1 3- and 2.5-
fold, respectively, relative to a control siRNA (Figure 6b). Iso-
genic MCF10A cells with an engineered deletion of TP53 (TP53-/-
MCF10A) showed a lower level of DNp63 protein (Figure 6c),
higher level of MDM2 (Figure 6d), BRCA1 (Figure 6e), TAp63
(Figure 5e), and lumenal cytokeratin KRT18 (Supplementary
Figure S5a, b). Upregulation of KRT18 in TP53-/- MCF10A cells is
likely mediated by TP63 as a knockdown of DNp63 led to a further
increase in KRT18, while a knockdown of TAp63 resulted in a
decrease of KRT18 and increase of the basal KRT5 (Supplementary
Figure S5).
We showed earlier that, in contrast to normal cuboidal MCF10A
cells, a suppressed function ofDNp63 in lumenal MCF7, basal EMT-
like MDA-MB-231, and sparsely seeded basal MCF10A cells corre-
lated with a nucleolar localization of the protein (Figure 3b, c,
Figure 5a, and Figure 6a). A genetic deletion of TP53 in MCF10A
led to a relocation of the DNp63 protein from the nucleoplasm into
nucleoli either completely (Figure 6e) or partially, filling out the
entire nucleus including the nucleolar space (Figure 3c). Interes-
tingly, the deletion of TP53 and localization of DNp63 also affected
the distribution of the nucleophosminwithin nucleoli (Figure 3e, and
Figure 7). In all cells showing a nucleolar localization of DNp63
(MCF7, MDA-MB-231, TP53-/- MCF10A, or siDNp63 MCF10A)
nucleophosmin is rather evenly distributed within nucleoli, while
in TP531/1MCF10A cells it is mostly found at the periphery of each
nucleolus (Figure 3c, Figure 7). Nucleophosmin is an important
nucleolar protein supporting translation of ribosomal proteins and
associated with the nucleolar fibrillar component. Its localization
Figure 3 | Nucleolar localization of DNp63 correlates with EMT and
functional inactivation. (a) Phase contrast images (upper row)
demonstrate an epithelial cobblestone-like (MCF10A and HCC1937) and
mesenchymal (MDA-MB-231)morphology of human basalmammary cell
lines. In cobblestone-like cells, DNp63 is excluded from nucleoli
(arrowheads, second row). In mesenchymal-like cells, DNp63 is found in
nucleoli (arrow). Functional inactivation of DNp63 using HDAC1
inhibitor trichostatin A (1TSA, third row) leads to a relocation of DNp63
into nucleoli in all cell lines. (b) MCF10A cells plated at a low density
spontaneously undergo EMT and demonstrate a mesenchymal
morphology. In these cells DNp63 is found predominantly in nucleoli
(arrows). Insets demonstrate higher power views of selected cells in
corresponding samples. (c) Co-staining ofDNp63 with a nucleolar marker
nucleophosmin (NPM) showing a nucleolar localization ofDNp63 protein
in MDA-MB-231, MCF7 and TP53-/- MCF10A cells, but not the parental
MCF10A cells. Red,DNp63; blue, DAPI. Scale bars correspond to 20 mm in
(a–b), and 10 mm in (c).
www.nature.com/scientificreports
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depends on the functional state of nucleoli28. Although the connec-
tion between nuclear and nucleolar distribution of DNp63 and
nucleophosmin is unclear, localization of nucleophosmin can serve
as an additional indicator of TP53-related effects in MCF10A cells.
Remarkably, while TAp63, MDM2, and BRCA1 were upregulated in
TP53-/-MCF10A cells, a siRNA-mediated suppression of any of these
genes restored both a nucleolus-excluded nucleoplasmic localization
of DNp63 and a peripheral distribution of nucleophosmin within
nucleoli (Figure 7). This suggests that these three induced genes
are functionally relevant and their pharmacological targeting may
help to treat TP53-deficient tumors by restoring the activity of
DNp63 and the associated basal epithelial qualities.
Figure 4 | TP53 andDNp63 negatively regulate TAp63. (a) mRNA expression was measured using qRT-PCR in Trp53-/- and wild type mMECs cultured
for 14 days. Values represent fold changes relative to wild type mMECs. Notice a sharp increase in TAp63 in Trp53-/- mMECs. (b) Immunofluorescence
staining of immortalized Trp53-/- mMECs showing a nucleolar localization of TAp63 isoform (red). Nuclei are counterstained with DAPI shown in blue.
(c) TAp63 is detected in nucleoli in all tested stablemammary epithelial cell lines. (d) qRT-PCR showing a 36-fold increase in themRNA level of TAp63 in
MCF10A cells after DNp63 was inhibited using TSA treatment. (e) qRT-PCR showing a two-fold increase in expression of TAp63 in isogenic TP53-/-
compared with its parental TP531/1MCF10A cell line. (f–g) qRT-PCR showing a negative regulation of TAp63 by DNp63 in TP531/1MCF10A cells (f),
and their mutual suppression in TP53-/- MCF10A cells (g). Scale bars correspond to 20 mm.
www.nature.com/scientificreports
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Discussion
In spite of various observations suggesting a cell type-specific role for
TP53 in epithelial tissues, particularly inmammary epithelia, no such
role has been described for in vivo models of Trp53. Here we found
that a loss of Trp53 in mMECs has a negative effect on expression of
basal-like features while having the opposite effect on the lumenal
features, when a simple in vitro differentiation assay was used. The
exact factors causing primary mMECs to change their phenotype
from lumenal to basal, and from basal to mesenchymal in our assay
are unclear. However, an epidermal growth factor (EGF) present in
the medium is shown to promote the expansion of myoepithelial
cells29. Adhesive culture conditions also support the expression of
basal and inhibit lumenal cytokeratins30. Cells cultured on plastic in
the absence of a basement membrane upregulate TGFb1, which
promotes EMT and stimulates MDM2 expression31,32. Thus, a
combined effect of EGF and adhesive culture conditions are likely
the key factors underlying the assay.
Our data suggest that a network of at least four genes maintain the
cell type identity of mammary epithelial cells: TP53 and DNp63 are
required for the basal subtype, while MDM2 and BRCA1 prevent
their expression, thus, supporting lumenal cells (Figure 8). The key
role of DNp63 in the maintenance of epidermal stem cells and basal
epithelial cell types is well established, although mechanistic details
are still being revealed33. However, this is the first report showing a
direct role of TP53 in regulating DNp63. TP53 supports the overall
expression level of the DNp63 protein as well as prevents its trans-
location from the nucleoplasm into nucleoli. As TP53 is a transcrip-
tion factor, and validated TP53-binding sites are found in the
promoter region of both isoforms of TP63 (Supplementary Figure
1), the transcriptional regulation is likely to be direct. Future studies
Figure 5 | DNp63 is suppressed by MDM2 and BRCA1 in lumenal MCF7 cells. (a) Immunofluorescence showing the DNp63 protein (top row) in
MCF7 cells treated as indicated above. BRCA1 protein (second row) is readily detectable in control cells, but disappears after treatments promoting
expression of DNp63. MDM2 protein (third row) correlates with the expression of BRCA1. (b) qRT-PCR showing fold change in mRNA levels for
DNp63, MDM2, and BRCA1 following treatments indicated above. (c) Western blot confirming an effective reduction of BRCA1 protein level and
stabilization of the TP53 protein after treatments indicated above. F12, cells were cultured in DMEM/F12 medium instead of the regular DMEM;
Serdemetan, cells treated with MDM2 inhibitor as described in Materials and Methods; siBRCA1 and siMDM2, cells treated with siRNAs targeting
corresponding genes. Scale bars correspond to 20 mm.
www.nature.com/scientificreports
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will elucidate mechanistic details of such regulation. A TP53-
mediated nucleolar translocation of the DNp63 protein is also
reported here for the first time. Although the underlying mechanism
is unclear, nucleoli are known to play important roles in cell cycle
control, stress responses, and aging34. Such spatial sequestration and
the ubiquitin-mediated protein degradation belong to essential nuc-
leolar functions35. Our data demonstrate that a nucleolar sequest-
ration of the DNp63 protein is functionally equivalent to its
inactivation using HDAC1/2 inhibitors and its knockdown leading
to the upregulation of MDM2 and BRCA1. In turn, high level of
MDM2 may suppress the basal-like epithelial differentiation by
inhibitingDNp63 either via inactivation of TP53 or by directly inter-
acting with DNp63 and promoting its nuclear export and proteaso-
mal degradation mediated by the E3 ubiquitin ligase activity of
FBXW736. Changes in MDM2 expression correlated with those of
BRCA1 in our experiments. A deletion of BRCA1 in mammary
progenitor cells prevents their lumenal differentiation, which may
explain the bias towards a basal-like rather than lumenal phenotype
for BRCA1-deficient breast cancers37. Our results offer an alternative
explanation for this phenomenon. As an inactivation of BRCA1
would likely lead to replication defects and DNA damage, it would
elicit an activation of cell cycle checkpoints including the TP53 path-
way, which could then promote the expression of DNp63 and basal-
like differentiation.
In agreement with published reports, we show that a deletion of
Trp53 in mMECs eventually leads to EMT and an unlimited cell
proliferation32,38. At the molecular level, this correlates with an upre-
gulation of vimentin, MDM2, and TAp63, and a suppression of
cytokeratins along with a nucleolar sequestration of DNp63. Once
again, the transcription of TAp63 may be directly regulated by TP53
as several active binding sites for TP53 are identified in the promoter
of TAp63, and an increase in TAp63 expression is independently
Figure 6 | TP53 and DNp63 negatively regulate MDM2 and BRCA1 in basal-like cells. (a) Untreated MCF10A cells express high levels of DNp63, and
low levels of BRCA1 and MDM2. Cells plated at a low density translocate DNp63 to nucleoli, and elevate expression of BRCA1, and MDM2.
(b) Knockdown of TP63 (siTP63) results in upregulation of BRCA1 andMDM2. (c)Western blot confirming an efficient siRNA-mediated knockdown of
BRCA1 and DNp63 proteins, and lack of TP53 in TP53-/- MCF10A cells. Notice a higher level of DNp63 protein in BRCA1-depleted TP53-mutant cells.
Asterisk indicates a 75 kDa band from a molecular weight marker loaded in the same lane as the siMDM2 sample. (d) TP53-deficiency in MCF10A cells
leads to an increase in MDM2 mRNA level as measured by qRT-PCR. (e) Immunofluorescence staining of TP53-/- and its parental isogenic TP531/1
MCF10A cell lines demonstrates a ubiquitous relocation ofDNp63 protein from the nucleoplasm inTP531/1 cells (arrowheads) to nucleoli inTP53-/- cells
(arrows), and upregulation of BRCA1 in TP53-/- cells. Insets illustrate the differences at a higher magnification. Scale bars correspond to 20 mm.
www.nature.com/scientificreports
SCIENTIFIC REPORTS | 4 : 4663 | DOI: 10.1038/srep04663 7
confirmed in TP53-/- isogenic MCF10A cells. TAp63 can transacti-
vate MDM239, which, as discussed earlier, suppresses DNp63 leading
to a loss of the epithelial differentiation. TAp63 can also promote
EMT independently from DNp63 via the upregulation of transcrip-
tion factors Slug and Snail20. As the TAp63 protein was found in
nucleoli in all mammary epithelial cell lines irrespective of the his-
tological subtype or EMT status, it may not be solely responsible for
the EMT. Consistently, TAp63 has been linked to sustaining a long-
term self-renewal capacity of epidermal progenitor cells23,40, thus
adding to the transforming ability of a mutant TP53.
Taken together, our results demonstrate a role for TP53 in the
EMT and differentiation of mammary epithelia, which is closely
linked to the regulation of alternative isoforms of TP63. This role
of TP53 may explain the prevalence of sarcomas in Trp53-deficient
animal models and Li-Fraumeni syndrome patients, and shed light
on the mechanisms underlying observed differences in TP53 muta-
tion spectra between lumenal and basal breast cancers.
Methods
Mice. B6.129S2-Trp53tm1Tyj/J mice carrying a deletion of exons 2–6 of Trp53 were
obtained from The Jackson Laboratory and maintained in a standard special
pathogen free (SPF) facility at theUniversity ofHelsinki. The reportermice were from
Prof. Janet Sawicki laboratory from the Lankenau Institute forMedical Research41. All
animal experiments were approved by the National Animal Experiment Board of
Finland (Ela¨inkoelautakunta, ELLA) in compliance with the Finnish Act on Animal
Experimentation (62/2006).
Cell culture and drug treatments.MCF7, HCC1937, MDA-MB-231, and MCF10A
cell lines were obtained from the American Type Culture Collection (ATCC). X-
MAN isogenic TP53-/- and a matched parental MCF10A cells were purchased from
the Horizon Discovery Inc. (cat # HD 101-005, and # HD PAR-024, respectively)42.
Dulbecco’s modified Eagle’s medium (DMEM, Lonza) was used to maintain MCF7
and MDA-MB-231 cells. HCC1937 cells were cultured in RPMI 1640 (Lonza). Both
media were Supplementaryemented with 10% fetal bovine serum (FBS), glutamine,
penicillin, and streptomycin. PrimarymMECswere isolated from inguinal mammary
glands of adult virgin mice according to a protocol published elsewhere43. Isolated
mMECs were cultured in standard tissue culture plastic plates in the DMEM/F12
growth medium without phenol red (Gibco) Supplementaryemented with 5% horse
serum, 10 mg/ml insulin, 20 ng/ml EGF, 5 ng/ml choleratoxin, 500 ng/ml
hydrocortison, penicillin, and streptomycin. MCF10A cells were cultured in the same
medium. Cells were treated with Trichostatin A (Selleck) at 1–5 mM, or with XI-011/
NSC 146109 (R&D) at 0.5 mM concentrations for 48 h. Treatments with Serdemetan
(JNJ-26854165, Selleck) were carried out at 10 mM for 72 h.
Immunofluorescence. Cells grown on glass coverslips were fixed with a 4%
paraformaldehyde (PFA) for 15 minutes or 100% methanol for 10 minutes. Primary
antibodies were used as follows: goat anti-TAp63 (Santa Cruz, sc-8608, diluted 1550),
Figure 7 | Inhibition of TAp63, BRCA1, or MDM2 in TP53-/- cells restores the nucleoplasmic localization of DNp63. Isogenic TP531/1 or TP53-/-
MCF10A cells were co-stained forDNp63 (red) and NPM (nucleophosmin, green) to reveal their distribution relative to nucleoli after siRNA treatments
indicated above. Yellow frames highlight a suppressed state of DNp63. Notice that in these cells DNp63 is found in nucleoli as well as in the nucleoplasm,
and NPM is almost evenly distributed within nucleoli (arrows). Knockdown of TAp63 and others restores a nucleolar exclusion of DNp63 and a
peripheral distribution of NPM within nucleoli (arrowheads).
Figure 8 | Model describing the role of TP53 inmammary epithelia.TP53
prevents translocation of DNp63 from the nucleoplasm into nucleoli.
Active TP53 and a nucleoplasmic DNp63 inversely correlate with MDM2,
BRCA1, and TAp63. MDM2 and BRCA1 in luminal cells inhibit TP53,
thus preventing the nucleoplasmic expression of DNp63 and suppressing
the basal-like differentiation. Loss of TP53 leads to an upregulation of
TAp63, which is associated with an unlimited cell proliferation rather than
a particular epithelial subtype. Relocation of DNp63 to nucleoli in basal
epithelial cells is associated with EMT.
www.nature.com/scientificreports
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rabbit anti-Ki67 (Abcam, ab15580, diluted 15200), goat anti-DNp63 (Santa Cruz, sc-
8609, diluted 15100), rabbit anti-MDM2 (Abcam, ab58530, diluted 15100), mouse
monoclonal anti-Krt18 (Abcam, ab668, diluted 15100), mouse monoclonal anti-p53
(Abcam, ab26, diluted 15100), mouse monoclonal anti-p53 (Abcam, PAb 240,
diluted 15100), mouse anti-human BRCA1 (Calbiochem, OP92, diluted 15100), and
mouse monoclonal anti-Nucleophosmin (Invitrogen, FC-61991, diluted 15200, a
kind gift of Karita Peltonen and Prof. Marikki Laiho). Secondary antibodies were
donkey anti-goat IgG conjugated with Texas Red (Invitrogen, diluted 151000), or
goat anti-rabbit IgG conjugated with Alexa Fluor 594 (Invitrogen, diluted 151000), or
goat anti-mouse IgG conjugated with Alexa Fluor 488 (Invitrogen, diluted 151000).
Images were taken with a Nikon Eclipse 90i fluorescence microscope and processed
using Nikon NIS-Elements AR software.
Gene Silencing and expression analysis. Transient gene-specific knockdowns were
carried out using following siRNAs (Qiagen): siMDM2 (cat. # SI02653392, target
sequence 59-AACCTGAAATTTATTCACATA-39), siBRCA1 (cat. # SI02654575,
target sequence 59-CAGCAGTTTATTACTCACTAA-39), siTP63 (cat. #
SI04951443, target sequence 59-AACCATGAGCTGAGCCGTGAA-39), siTP53 (cat.
# SI02655170, target sequence 59-AAGGAAATTTGCGTGTGGAGT-39). Custom
siRNAs against TAp63 (target sequence 59-GCGACAAACAAGATTGAGA-39) or
DNp63 (target sequence 59-TGCCCAGACTCAATTTAGT-39) were ordered from
Sigma. siRNA duplexes at a final concentration 20 nM were transfected using
Lipofectamine RNAiMAX (Invitrogen) according to manufacturer’s instructions.
Total RNA was extracted using the NucleoSpin RNA II kit (Macherey-Nagel)
48 hours after siRNA transfection. cDNA was synthesized using Revert Aid First
Strand cDNA Synthesis Kit (MBI-Fermentas). Gene expression was measured by
real-time quantitative PCR (qRT-PCR) using the SYBR-Green-based detection
method and CFX384 cycler (Bio-Rad). Primer sequences are listed in Supplementary
Table 1. Gene expressionwas normalized relative toGAPDHand quantified using the
CFX software (Bio-Rad).
Western blotting. Cells were lysed in a RIPA buffer. 15 mg proteins were separated
using NuPAGE 4–12% Bis-Tris, precast gels (Invitrogen) according to
manufacturer’s instructions, and transferred to the Immobilon-FL PVDFmembrane
(Millipore). Membranes were incubated with primary antibodies in a blocking buffer
(1xTBS, 0.05% Tween 20, 5% Milk) overnight at 14uC. After incubation with
fluorescently labeled secondary antibodies (goat-anti-mouse IRDye 800 CW or goat-
anti-rabbit IRDye 680 LT, LI-COR) diluted 1510000, membranes were scanned using
a fluorescence scanner Odyssey (LI-COR Biosciences).
Chromatin immunoprecipitation followed by quantitative PCR (ChIP-qPCR).
ChIP assay was performed as previously described44. Briefly, MCF10A cells were
cross-linked with 1% formaldehyde and quenched with 125 mM glycine. Nuclei were
isolated and lysed in SDS lysis buffer (50 mM Tris-HCl, pH 8.1, with 0.5% SDS,
10 mM EDTA and Complete Protease Inhibitor cocktail). Nuclear extracts were
sonicated to generate chromatin fragment with an average size of 0.6 kb using a
Q800R sonicator (QSonica). Chromatin lysate was cleared by centrifugation and
diluted with 6 volumes of cold IP buffer (EDTA 2 mM, NaCl 150 mM, Tris-HCl
20 mM, pH 8.0, Triton X-100 1%, Complete Protease Inhibitor), and incubated
overnight at 4uC with the Dynabead/antibody complex (80 ul Dynabead protein G
(Invitrogen) contained 8 mg antibody against TP53 (sc-126, Santa Cruz
Biotechnology) or control IgG (normal mouse IgG, sc-2025, Santa Cruz
Biotechnology) in Blocking buffer (0.5% BSA in IP buffer). After washing, the
protein-DNA complex was eluted with 100 ml extraction buffer (1 mM EDTA, 1%
SDS in 10 mMTris-HCl, pH 8.0), and treated with Proteinase K (1 mg/ml) and NaCl
(0.3 M) overnight at 65uC. Then RNase A (0.2 mg/ml) was added for 1 h at 37uC.
DNAwas purified with theMini-Elute PCR purification kit (Qiagen) and analyzed by
qPCR with EpiTect ChIP qPCR Primer set for TP63 (cat # GPH1009765(1)03A,
Qiagen). A relative enrichment of the target DNA fragments was assessed by
calculating the immunoprecipitation efficiency above fragment-specific background
(IgG control) followed by normalization to the occupancy level observed for the
control region amplified with primers ChIPneg135f (59- TGCCTCAGATTTG-
GAGTGCT-39) and ChIPneg135r (59- GAGAAGCCTCTGAGGAGGGA-39).
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